Strategic research collaboration to advance MTx's recombinant polyclonal IgG technology
Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by CSL, a license fee, and development and sales milestones of up to CHF 265 million (USD 328 million)
Provides further validation of MTx's proprietary DROPZYLLA® technology platform
Schlieren / Zurich, Switzerland, 9 February, 2026, Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases, for MTx's recombinant polyclonal IgG technology.
Under the Collaboration and Option Agreement, MTx will develop recombinant polyclonal IgG products, leveraging its proprietary DROPZYLLA® technology platform for cloning human antibody repertoires and polyclonal antibody expression, and CSL is being granted an option to exclusively license recombinant polyclonal IgG products from MTx. The agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option, a license fee, and development and sales milestones totalling up to CHF 265 million (USD 328 million) for the first product, ...
